Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Nature Medicine, Journal Year: 2017, Volume and Issue: 23(6), P. 703 - 713

Published: May 8, 2017

Language: Английский

---

A view on drug resistance in cancer

Nature, Journal Year: 2019, Volume and Issue: 575(7782), P. 299 - 309

Published: Nov. 13, 2019

Language: Английский

---

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

The Lancet Oncology, Journal Year: 2016, Volume and Issue: 17(4), P. 425 - 439

Published: March 3, 2016

Language: Английский

---

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Cancer Discovery, Journal Year: 2014, Volume and Issue: 4(9), P. 998 - 1013

Published: July 16, 2014

Abstract Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX mostly retain principal histologic genetic characteristics their donor remain stable across passages. These have shown to be predictive clinical outcomes are being used preclinical drug evaluation, biomarker identification, biologic studies, personalized medicine strategies. This article summarizes current state art this field, including methodologic issues, available collections, practical applications, challenges shortcomings, future directions, introduces a European consortium models. Significance: increasingly translational useful screening, development, evaluation review provides timely overview key detailed discussion directions field. Cancer Discov; 4(9); 998–1013. ©2014 AACR.

Language: Английский

---

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

New England Journal of Medicine, Journal Year: 2015, Volume and Issue: 373(3), P. 209 - 219

Published: June 1, 2015

Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 CDK6), which promote progression from the G1 phase to S cell cycle. We assessed efficacy palbociclib (an inhibitor CDK4 CDK6) fulvestrant in advanced cancer.This 3 study involved 521 patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative that had relapsed or progressed during prior endocrine therapy. randomly assigned a 2:1 ratio receive placebo fulvestrant. Premenopausal perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary points included overall survival, objective response, rate clinical benefit, patient-reported outcomes, safety. A preplanned interim analysis performed by an independent data safety monitoring committee after 195 events disease death occurred.The median survival 9.2 months (95% confidence interval [CI], 7.5 not estimable) palbociclib-fulvestrant 3.8 CI, 3.5 5.5) placebo-fulvestrant (hazard for death, 0.42; 95% 0.32 0.56; P<0.001). most common grade adverse group were neutropenia (62.0%, vs. 0.6% group), leukopenia (25.2% 0.6%), anemia (2.6% 1.7%), thrombocytopenia (2.3% 0%), fatigue (2.0% 1.2%). Febrile reported palbociclib-treated placebo-treated patients. discontinuation due 2.6% 1.7% placebo.Among metastatic who therapy, combined resulted longer than alone. (Funded Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).

Language: Английский

---

Treating cancer with selective CDK4/6 inhibitors

Nature Reviews Clinical Oncology, Journal Year: 2016, Volume and Issue: 13(7), P. 417 - 430

Published: March 31, 2016

Language: Английский

---

Signal Transduction in Cancer

Cold Spring Harbor Perspectives in Medicine, Journal Year: 2015, Volume and Issue: 5(4), P. a006098 - a006098

Published: April 1, 2015

Richard Sever1 and Joan S. Brugge2 1Cold Spring Harbor Laboratory, Cold Harbor, New York 11724 2Harvard Medical School, Department of Cell Biology, Boston, Massachusetts 02115 Correspondence: joan_brugge{at}hms.harvard.edu

Language: Английский

---

Liquid biopsy and minimal residual disease — latest advances and implications for cure

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 409 - 424

Published: Feb. 22, 2019

Language: Английский

---

Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

Science, Journal Year: 2014, Volume and Issue: 345(6193), P. 216 - 220

Published: July 10, 2014

Circulating tumor cells (CTCs) are present at low concentrations in the peripheral blood of patients with solid tumors. It has been proposed that isolation, ex vivo culture, and characterization CTCs may provide an opportunity to noninvasively monitor changing patterns drug susceptibility individual as their tumors acquire new mutations. In a proof-of-concept study, we established CTC cultures from six estrogen receptor-positive breast cancer. Three five lines tested were tumorigenic mice. Genome sequencing revealed preexisting mutations PIK3CA gene newly acquired receptor (ESR1), gene, fibroblast growth factor (FGFR2), among others. Drug sensitivity testing multiple potential therapeutic targets. With optimization culture conditions, this strategy help identify best therapies for cancer over course disease.

Language: Английский

---

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

Cancer Cell, Journal Year: 2018, Volume and Issue: 34(3), P. 427 - 438.e6

Published: Sept. 1, 2018

Language: Английский

---